ripretinib
Trade name: Qinlock
Approved
May 15, 2020
Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing. — Wikipedia
Clinical trial activity
11 trials · 4 clinical orgs · 1 marketing orgs
Earliest trial started Oct 1, 2015 (NCT02571036)
Timeline
2010s
- Oct 2, 2014
Orphan Drug Designation
- Jan 1, 2015
Deciphera Pharmaceuticals LLC — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2018
Deciphera Pharmaceuticals LLC — Earliest Phase 3 Sponsor(trial)
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
- May 15, 2020
Deciphera Pharmaceuticals LLC — Earliest FDA Approval
- May 15, 2020
Deciphera Pharmaceuticals LLC — Marketing Organization
- May 15, 2020
Deciphera Pharmaceuticals LLC — NDA Secondary Org
- May 15, 2020
Deciphera Pharmaceuticals LLC — NDA Organization
Indications
Approved for
Mechanism of action
KIT antagonist
- Stem cell growth factor receptorINHIBITOR
Stem cell growth factor receptor inhibitor
Active against wild type, primary, and secondary mutations. Also inhibits PDGFRB, TIE2, VEGFR2, and BRAF in vitro.
Platelet-derived growth factor receptor alpha inhibitor
Active against wild type, primary, and secondary mutations. Also inhibits PDGFRB, TIE2, VEGFR2, and BRAF in vitro.
Approval history
- approvedPriority reviewFast trackBreakthroughMay 15, 2020
Chemistry & pharmacology
SMILES
CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21- Mol. weight
- 510.37 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaRipretinib ↗
- ChEMBLCHEMBL4216467 ↗
Also known as
- dcc-2618
- dcc-2618
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05734105 | Phase 3 | Dec 31, 2023 | Deciphera Pharmaceuticals LLC |
| NCT05957367 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2023 | Deciphera Pharmaceuticals LLC, Pfizer |
| NCT05080621 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Deciphera Pharmaceuticals LLC |
| NCT05132738 | N/A | Aug 1, 2021 | Jiao Tong University |
| NCT04530981 | Phase 1 | Nov 30, 2020 | Deciphera Pharmaceuticals LLC |
| NCT04633122 | Phase 2 | Nov 25, 2020 | Zai Lab Pty. Ltd. |
| NCT04282980 | Phase 2 | Apr 30, 2020 | Zai Lab Pty. Ltd. |
| NCT03673501 | Phase 3 | Dec 31, 2018 | Deciphera Pharmaceuticals LLC |
| NCT03353753 | Phase 3 | Feb 27, 2018 | Deciphera Pharmaceuticals LLC |
| NCT02571036 | Phase 1 | Oct 1, 2015 | Deciphera Pharmaceuticals LLC |
| NCT04148092 | N/A | — | Deciphera Pharmaceuticals LLC |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Deciphera Pharmaceuticals LLC | For profit | 8 | 8 | 4 | 2015 |
| Zai Lab Pty. Ltd. | For profit | 2 | 2 | 1 | 2020 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Pfizer | For profit | 1 | 0 | 1 | 2023 |
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Deciphera Pharmaceuticals LLC | For profit | MKTG | May 15, 2020 |
| Deciphera Pharmaceuticals LLC | For profit | SYN | May 15, 2020 |
| Deciphera Pharmaceuticals LLC | For profit | NDA2 | May 15, 2020 |
| Deciphera Pharmaceuticals LLC | For profit | NDA | May 15, 2020 |